Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The
purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can
help improve the health condition of participants infected with COVID-19. This is the first
in-human study of this investigational product specifically in patients with severe COVID-19.
Currently there are no FDA approved medications that improve the chance of survival in
patients diagnosed with COVID-19. However there are usual treatments currently being used to
help treat COVID-19 patients and BMS-986253 will be compared to these standard of care
treatments in this study.